GLAXF - GSK's 2-Drug Combo For HIV Could Threaten Gilead
Gilead's (GILD) vaunted HCV franchise grew quarterly revenue by double digits in Q2 2018. HCV was less than 20% of total revenue, down from over 40% in the year earlier period. Its HIV franchise will likely drive the narrative from here. That could be problematic as GlaxoSmithKline (GSK), (GLAXF), (GLXKY), (GLXQY) continues to seek innovations in the HIV space. Reports suggest Glaxo's long-acting injection given once a month has proven it can control the AIDS virus as effectively as standard daily pills:
GSK's majority-owned ViiV